CJC-1295 (without DAC) vs Thymosin Beta-4
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC-1295 (without DAC) and Thymosin Beta-4 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 (without DAC) Thymosin Beta-4
Weight 3,367.97 Da 4,963.44 Da
Half-life 30 minutes - 2 hours Dose-dependent; relatively short (exact values not established)
Chain 30 amino acids 43 amino acids
Type GHRH analog Thymosin peptide
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
CJC-1295 (without DAC) Thymosin Beta-4
Status Well Studied Well Studied
References 5 studies 4 studies
Latest November 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.